drugset / Trial / NCT06682572
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
Phase 2
Active not recruiting
16 enrolled
Verastem, Inc.
Japanese Gynecologic Oncology Group · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will confirm the safety and efficacy of avutometinib in combination with defactinib in Japanese patients with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Timeline
- Start
- 2024-10-30
- Primary completion
- 2025-12
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avutometinib | Small molecule | 3.2 mg | Oral |
| Subject | Defactinib | Small molecule | 200 mg | Oral |